Insulin Lispro in pregnancy - retrospective analysis of 33 cases and matched controls

Summary

Aims/hypothesis: To evaluate if the application of Lispro insulin in pregnancy increases the risk for malformations or unusual pregnancy courses.

Methods: Diabetes specialists were contacted in Germany and Austria and asked to report women with diabetes who had been treated with Lispro during pregnancy. Furthermore they were asked to report another pregnant diabetic woman treated with regular insulin with similar HbA_1c and age for each Lispro case. Following data were requested: age, first HbA_1c in pregnancy and time of analysis, start and duration of Lispro treatment, ultrasound examination, chorionic villi biopsy, amniocentesis, unusual pregnancy courses, standard examination of the new-born for any malformation. Two-sided 95% confidence limits (95%-CI) for risk differences of proportions of malformations or unusual pregnancy courses were calculated.

Results: 33 pregnant diabetic women with Lispro and 27 with regular insulin treatment were analysed (mean age 28.3 years (17-41)and 30.1 (19-40); mean HbA_1c 6.9% (4.5-10.7) and 6.8% (4.7-9.8), respectively). There were four malformations or unusual pregnancy course (spontaneous abortion; elective interruption because of multiple malformations; heart malformations and hyaline membrane syndrom; premature birth) in the Lispro and one malformation (dyplastic hip) in the regular insulin group.

Risk differences in proportions of malformation or unusual pregnancy courses were 8% (95%-CI: - 5% to 21%).

Conclusions/Interpretation: Risk differences for malformations or unusual pregnancy courses were not higher in the insulin Lispro group compared to the controls. However, we observed four malformations or unusual pregnancy courses in the Lispro group. A case-control study is suggested to get a precise risk estimate.

Key words:

Insulin Lispro - Diabetes mellitus - Pregnancy - Congenital malformation - Spontaneous abortion

References

• 1 Anderson J H, Brunelle R L, Koivisto V A, Pfutzner A, Trautmann M E, Vignati L, Di Marchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment.  Diabetes. 1997;  46 265-270
• 2 Burley D M. The rise and fall of Thalidomide.  Pharm Med. 1988;  3 231-237
• 3 Combs C A, Gunderson E, Kitzmiller J L, Gavin L A, Main K. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy.  Diabetes Care. 1992;  15 1251-1257
• 4 Diamond T, O'Brien M. Possible adverse fetal effect of insulin Lispro.  N Engl J Med. 1997;  337 1009-1010 (letter)
• 5 Fleming D M, Knox J D, Crombie D L. Debendox in early pregnancy and fetal malformation.  BMJ. 1981;  283 99-101
• 6 Freinkel N, Metzger B E. Pregnancy as a tissue culture experience: the critical implications of maternal metabolism for fetal development. In: Elliot K et al (eds). Pregnancy, metabolism, diabetes and the fetus. Ciba foundation Symposium 63. Excerpta Medica, Amsterdam 1979: 3-23
• 7 Fuhrmann K, Reiher H, Semmler K, Glockner E. The effect of intensified conventional insulin therapy before and during early pregnancy on the malformation rate in offspring of diabetic mothers.  Exp Clin Endocrinol. 83 ((2)) 1984;  173-177
• 8 Gabbe S G, Mestman J H, Freeman R K, Goebelsmann U T, Lowensohn R I, Nochimson D, Cetrulo C, Quilligan E J. Management and outcome of pregnancy in diabetes mellitus, classes B to R.  Am J Obstet Gynecol. 129 ((7)) 1977;  723-732
• 9 Greene M F, Hare J W, Cloherty J P, Benacerraf B R, Soeldner J S. First-trimester hamoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy.  Teratology. 39 ((3)) 1989;  225-231
• 10 Hanson U, Perrson B, Thunell S. The relation between HbA_1c in early diabetic pregnancy and the occurrence of spontaneous abortion and malformation in Sweden.  Diabetologia. 1990;  33 100-104
• 11 Hoffman J IE. Congenital heart disease: incidence and inheritance.  Ped Clin North Am. 37 ((1)) 1990;  25-43
• 12 Holmes L B. Teratogen update: bendectin.  Teratology. 1983;  27 277-281
• 13 Jovanovic L, Ilic S, Pettitt D J, Hugo K, Gutierrez M, Bowsher R R, Bastyr E J. Metabolic and immunologic effects of insulin lispro in gestational diabetes.  Diabetes Care. 1999;  22 1422-1427
• 14 Jovanovic-Peterson L, Peterson C M, Reed G F, Metzger B E, Mills J L, Knopp R H, Aarons J H. Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study.  Am J Obstet Gynecol. 1991;  164 103-111
• 15 Karlsson K, Kjellmer I. The outcome of diabetic pregnancies in relation to the mother's blood sugar.  Am J Obstet Gynecol. 112 ((2)) 1972;  213-220
• 16 Key T C, Giuffrida R, Moore T R. Predictive value of early pregnancy glycohemoglobin in the insulin-treated diabetic patient.  AM J Obstet Gynecol. 156 ((5)) 1987;  1096-1100
• 17 Kitzmiller J L, Gavin L A, Gin G D, Jovanovic-Peterson L, Main E K, Zigrang W D. Preconception care of diabetes. Glycemic control prevents congenital malformations.  JAMA. 265 ((6)) 1991;  731-736
• 18 Kotsanos J G, Vignati L, Huster W, Andrejasich C, Boggs M B, Jacobson A M, Marrero D, Mathias S D, Patrick D, Zalani S, Anderson J. Health-related quality-of-life results from multinational clinical trials of insulin Lispro.  Diabetes Care. 20 ((6)) 1997;  948-958
• 19 Miller E, Hare J W, Cloherty J P, Dunn P J, Gleason R E, Soeldner J S, Kitzmiller J L. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers.  N Engl J Med. 304 ((22)) 1981;  1331-1334
• 20 Mills J. Malformation in infants of diabetic mothers.  Teratology. 1982;  25 385-394
• 21 Mills J L, Knoop R H, Simpson J L, Jovanovic-Peterson L, Metzger B E, Holmes L B, Aarons J H, Brown Z, Reed G F, Bieber F R. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis.  N Engl J Med. 318 ((11)) 1988;  671-676
• 22 Mills J L, Simpson J L, Driscoll S G, Jovanovic-Peterson L, Van Allen M, Aarons J H, Metzger B, Bieber F R, Knopp R H, Holmes L B. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception.  N Engl J Med. 319 ((25)) 1988;  1617-1623
• 23 Miodovnik M, Mimouni F, Tsang R C, Ammar E, Kaplan L, Siddiqi T A. Glycemic control and spontaneous abortion in insulin-dependent diabetic women.  Obstet Gynecol. 68 ((3)) 1986;  366-369
• 24 Miodovnik M, Skillman C, Holroyde J C. Elevated maternal glycohemoglobin in early pregnancy and spontaneous abortion among insulin-dependent diabetes mellitus.  Am J Obstet Gynecol. 153 ((4)) 1985;  439-442
• 25 Pedersen J. Congenital Malformation. In: Pedersen J (ed) The pregnant diabetic and her newborn: problems and management. 2nd ed Williams & Wilkins, Baltimore 1977: 191-197
• 26 Simpson J L, Elias S, Martin A O, Palmer M S, Ogata E S, Radvany R A. Diabetes in pregnancy, Northwestern University series (1977-1981). I. Prospective study of anomalies in offspring of mothers with diabetes mellitus.  Am J Obstet Gynecol. 146 ((3)) 1983;  263-270
• 27 Soverchia G, Perr P F. Two cases of malformation of a limb in infants of mothers treated with an antiemetic in a very early phase of pregnancy.  Pediatr Med Chir. 1981;  3 97-99
• 28 Stephens M DB. The pre-marketing establishment of the side-effect profile of a new drug. In: Stephens MDB, Talbot JCC, Routledge PA (eds) Detection of New Adverse Drug Reactions Macmillian Reference LTD, London 1988: 197-251
• 29 Wright A D, Nicholson H O, Pollock A, Taylor K G, Betts S. Spontaneous abortion and diabetes mellitus.  Postgraduate Med J. 59 ((691)) 1983;  295-298
• 30 Ylinen K, Raivio K, Teramo K. Hemoglobin A_1c predicts the perinatal outcome in insulin-dependent diabetic pregnancies.  Brit J Obstet Gynaec. 1981;  88 961-967